Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
Radiopharm Theranostics
About
  2. Companies
  3. Radiopharm Theranostics
  4. Products
  5. Radiopharm - Model PSA-mAb - ...

Radiopharm - Model PSA-mAb -Radioactive Drugs

SHARE

PSA-mAb is the invention of Professor David Ulmert formerly of Memorial Sloan Kettering and now UCLA.

Most popular related searches
prostate cancer
advanced prostate cancer
radioactive drug
prostate tissue
monoclonal antibody
cancer cell
prostate
  • PSA-mAb is a proprietary humanised monoclonal antibody, capable of targeting free human prostate kallikrein (PSA) in prostate cancer cells and internalising payload
  • The antibody platform enables a radiotheranostic applicable therapy of prostatic cancer through radioimmunotherapy as well as diagnostics of advanced prostate cancer
  • 10 000-fold + higher expression of KLK3 (PSA) in prostate tissue, compared to other tissue
  • [225Ac]-PSA mAb results in curative treatment by sustained tumour regression and a significant increase in median survival time
  • Data demonstrates a stable humanised antibody, without signs of degradation and aggregation